Q4 EPS Estimates for Cooper Companies Decreased by KeyCorp

The Cooper Companies, Inc. (NASDAQ:COO) – Equities researchers at KeyCorp reduced their Q4 2026 earnings estimates for Cooper Companies in a research report issued on Wednesday, September 9th. KeyCorp analyst B. Fishbin now expects that the medical device company will post earnings per share of $1.06 for the quarter, down from their prior estimate of $1.21. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Cooper Companies’ current full-year earnings is $4.53 per share.

A number of other analysts have also commented on COO. Needham & Company LLC reduced their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, September 10th. UBS Group lowered their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Mizuho set a $75.00 price objective on Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. dropped their target price on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Finally, Citigroup reiterated a “neutral” rating and set a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies presently has a consensus rating of “Hold” and an average target price of $71.47.

Cooper Companies Trading Down 2.1%

Cooper Companies stock opened at $54.12 on Monday. The business’s fifty day simple moving average is $69.58 and its two-hundred day simple moving average is $68.36. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 2.25 and a beta of 0.82. Cooper Companies has a 12 month low of $51.01 and a 12 month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the previous year, the firm posted $0.49 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS.

Cooper Companies declared that its board has approved a share repurchase plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Paul A. Keel acquired 4,701 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $53.18 per share, with a total value of $249,999.18. Following the acquisition, the director directly owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $54.11 per share, for a total transaction of $378,770.00. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 34,701 shares of company stock worth $1,880,039. 2.08% of the stock is owned by insiders.

Hedge Funds Weigh In On Cooper Companies

A number of large investors have recently made changes to their positions in the company. Avalon Trust Co bought a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $25,000. Root Financial Partners LLC increased its holdings in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the period. SJS Investment Consulting Inc. raised its position in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares in the last quarter. Elevation Wealth Partners LLC raised its position in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares in the last quarter. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies during the 2nd quarter worth $30,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.